Cadence Pharmaceuticals Stock Price, News & Analysis (NASDAQ:CADX)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Cadence Pharmaceuticals (NASDAQ:CADX)

Cadence Pharmaceuticals logoCadence Pharmaceuticals, Inc. (Cadence) is a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing products principally for use in the hospital setting. The Company has rights to one product, OFIRMEV (acetaminophen) injection, an intravenous (IV), formulation of acetaminophen. The Company in-licensed the United States, and Canadian rights to OFIRMEV from Bristol-Myers Squibb Company (BMS), which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. In March 2014, Mallinckrodt Plc acquired Cadence Pharmaceuticals, Inc. In March 2014, Mallinckrodt Plc completed the acquisition of Cadence Pharmaceuticals.

Receive CADX News and Ratings via Email

Sign-up to receive the latest news and ratings for CADX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Cadence Pharmaceuticals (NASDAQ:CADX) Frequently Asked Questions

What is Cadence Pharmaceuticals' stock symbol?

Cadence Pharmaceuticals trades on the NASDAQ under the ticker symbol "CADX."

Who are some of Cadence Pharmaceuticals' key competitors?

Has Cadence Pharmaceuticals been receiving favorable news coverage?

News headlines about CADX stock have been trending somewhat positive on Sunday, Accern Sentiment reports. Accern ranks the sentiment of media coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cadence Pharmaceuticals earned a media sentiment score of 0.12 on Accern's scale. They also gave press coverage about the biopharmaceutical company an impact score of 46.32 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.

How do I buy shares of Cadence Pharmaceuticals?

Shares of CADX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Cadence Pharmaceuticals?

Cadence Pharmaceuticals' mailing address is 12481 High Bluff Dr Ste 200, SAN DIEGO, CA 92130-3583, United States. The biopharmaceutical company can be reached via phone at +1-858-4361400.

MarketBeat Community Rating for Cadence Pharmaceuticals (CADX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  97 (Vote Outperform)
Underperform Votes:  86 (Vote Underperform)
Total Votes:  183
MarketBeat's community ratings are surveys of what our community members think about Cadence Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Cadence Pharmaceuticals (NASDAQ:CADX) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Cadence Pharmaceuticals (NASDAQ:CADX) Earnings History and Estimates Chart

Earnings by Quarter for Cadence Pharmaceuticals (NASDAQ:CADX)

Cadence Pharmaceuticals (NASDAQ CADX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/28/2014Q413($0.04)($0.05)$32.51 million$33.30 millionViewN/AView Earnings Details
11/5/2013Q3 2013($0.08)($0.08)$26.61 million$28.96 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.11)($0.14)$24.03 million$24.67 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.14)($0.02)$19.44 million$23.61 millionViewN/AView Earnings Details
3/7/2013Q4 2012($0.16)($0.15)ViewN/AView Earnings Details
11/5/2012Q312($0.19)($0.19)$14.16 million$13.90 millionViewN/AView Earnings Details
8/2/2012Q2 2012($0.24)($0.25)ViewN/AView Earnings Details
5/3/2012Q1 2012($0.23)($0.27)ViewN/AView Earnings Details
3/12/2012Q4 2011($0.27)($0.28)ViewN/AView Earnings Details
11/3/2011Q3 2011($0.36)($0.34)ViewN/AView Earnings Details
8/3/2011Q2 2011($0.38)($0.30)ViewN/AView Earnings Details
5/5/2011Q1 2011($0.34)($0.39)ViewN/AView Earnings Details
3/3/2011Q4 2010($0.33)($0.33)ViewN/AView Earnings Details
11/5/2010Q3 2010($0.24)($0.23)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.27)($0.24)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.24)($0.28)ViewN/AView Earnings Details
3/15/2010Q4 2009($0.29)($0.30)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.27)($0.23)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.21)($0.17)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.25)($0.24)ViewN/AView Earnings Details
3/12/2009Q4 2008($0.38)($0.37)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.38)($0.36)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.36)($0.41)ViewN/AView Earnings Details
5/6/2008Q1 2008($0.40)($0.42)ViewN/AView Earnings Details
3/12/2008Q4 2007($0.56)($0.50)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Cadence Pharmaceuticals (NASDAQ:CADX) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Cadence Pharmaceuticals (NASDAQ:CADX)

No dividend announcements for this company have been tracked by

Insider Trades

Cadence Pharmaceuticals (NASDAQ CADX) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for Cadence Pharmaceuticals (NASDAQ:CADX)

Cadence Pharmaceuticals (NASDAQ CADX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/17/2013William LarueCFOSell8,500$9.12$77,520.005,000View SEC Filing  
12/2/2013Scott ByrdSVPSell7,812$9.16$71,557.922,000View SEC Filing  
11/18/2013William LarueCFOSell36,000$7.30$262,800.005,000View SEC Filing  
7/22/2013Hazel M AkerSVPSell6,507$7.81$50,819.67View SEC Filing  
7/17/2013William R LarueCFOSell9,000$7.26$65,340.00View SEC Filing  
7/15/2013Hazel M AkerSVPSell6,508$7.34$47,768.72View SEC Filing  
6/27/2013William R LarueCFOSell9,000$7.20$64,800.00View SEC Filing  
6/10/2013Malcolm Lloyd-SmithSVPSell4,000$7.44$29,760.00View SEC Filing  
6/7/2013Scott A ByrdSVPSell67,115$7.53$505,375.95View SEC Filing  
3/12/2013Parters Vii L P DomainMajor ShareholderSell10,464$5.36$56,087.04View SEC Filing  
2/14/2013Parters Vii L P DomainMajor ShareholderSell8,714$5.00$43,570.00View SEC Filing  
2/1/2013Parters Vii L P DomainMajor ShareholderSell9,769$4.85$47,379.65View SEC Filing  
(Data available from 1/1/2013 forward)


Cadence Pharmaceuticals (NASDAQ CADX) News Headlines


SEC Filings

Cadence Pharmaceuticals (NASDAQ:CADX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Cadence Pharmaceuticals (NASDAQ:CADX) Income Statement, Balance Sheet and Cash Flow Statement


Cadence Pharmaceuticals (NASDAQ CADX) Stock Chart for Sunday, March, 18, 2018

Loading chart…

This page was last updated on 3/18/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.